Compare Stocks: TLPH, NERV, IMUX, and DERM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.47 -0.8%	$6.84	$4.31 ▼ $9.56	$210.83M	1.08	230,574 shs	122,961 shs
IMUX Immunic	$15.40 -5.5%	$15.05	$5.06 ▼ $17.43	$210.12M	1.41	184,281 shs	357,932 shs
NERV Minerva Neurosciences	$4.84 -5.7%	$4.53	$1.93 ▼ $12.46	$231.10M	-0.1	250,847 shs	135,733 shs
TLPH Talphera	$1.20 -2.4%	$1.25	$0.50 ▼ $1.57	$62.29M	0.69	321,937 shs	123,929 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	0.00%	-3.61%	+15.81%	+18.38%	-0.13%
IMUX Immunic	0.00%	-6.67%	+10.08%	+2.94%	+81.18%
NERV Minerva Neurosciences	0.00%	0.00%	+20.40%	-1.43%	+104.22%
TLPH Talphera	0.00%	+0.84%	-11.44%	+47.06%	+121.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.47 -0.8%	$6.84	$4.31 ▼ $9.56	$210.83M	1.08	230,574 shs	122,961 shs
IMUX Immunic	$15.40 -5.5%	$15.05	$5.06 ▼ $17.43	$210.12M	1.41	184,281 shs	357,932 shs
NERV Minerva Neurosciences	$4.84 -5.7%	$4.53	$1.93 ▼ $12.46	$231.10M	-0.1	250,847 shs	135,733 shs
TLPH Talphera	$1.20 -2.4%	$1.25	$0.50 ▼ $1.57	$62.29M	0.69	321,937 shs	123,929 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	0.00%	-3.61%	+15.81%	+18.38%	-0.13%
IMUX Immunic	0.00%	-6.67%	+10.08%	+2.94%	+81.18%
NERV Minerva Neurosciences	0.00%	0.00%	+20.40%	-1.43%	+104.22%
TLPH Talphera	0.00%	+0.84%	-11.44%	+47.06%	+121.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.25	Hold	$14.00	87.42% Upside
IMUX Immunic	3.00	Buy	$47.25	206.82% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	113.50% Upside
TLPH Talphera	2.25	Hold	$3.00	150.00% Upside

Current Analyst Ratings Breakdown

Latest TLPH, NERV, IMUX, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	TLPH Talphera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$68.18M	3.09	N/A	N/A	$1.14 per share	6.55
IMUX Immunic	N/A	N/A	N/A	N/A	$9.35 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
TLPH Talphera	$30K	2,076.40	N/A	N/A	$0.28 per share	4.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$11.43M	-$0.22	N/A	8.30	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.27	N/A	N/A	N/A	N/A	-87.28%	-51.36%	11/11/2026 (Estimated)

Latest TLPH, NERV, IMUX, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TLPH Talphera	-$0.0625	-$0.06	+$0.0025	-$0.06	N/A	N/A
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	0.64	1.59	1.41
IMUX Immunic	N/A	5.05	5.05
NERV Minerva Neurosciences	N/A	20.15	20.14
TLPH Talphera	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
IMUX Immunic	51.82%
NERV Minerva Neurosciences	34.56%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	14.53%
IMUX Immunic	5.49%
NERV Minerva Neurosciences	1.70%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	28.22 million	24.12 million	N/A
IMUX Immunic	70	13.64 million	12.90 million	Optionable
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
TLPH Talphera	19	51.91 million	50.09 million	Optionable

TLPH, NERV, IMUX, and DERM Headlines

Recent News About These Companies

Talphera Earnings Call Highlights Nafamostat Momentum

August 23, 2026 | tipranks.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

HC Wainwright Issues Positive Estimate for Talphera Earnings

August 17, 2026 | marketbeat.com

Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript

August 14, 2026 | finance.yahoo.com

HC Wainwright Has Negative View of Talphera FY2029 Earnings

August 14, 2026 | marketbeat.com

Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...

August 13, 2026 | uk.finance.yahoo.com

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

August 13, 2026 | seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | aol.comA

Talphera Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Talphera (NASDAQ:TLPH) Issues Earnings Results, Meets Estimates

August 12, 2026 | marketbeat.com

Talphera Q2 2026 earnings preview

August 11, 2026 | msn.com

Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen

August 8, 2026 | marketbeat.com

Talphera (TLPH) to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

August 5, 2026 | prnewswire.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

$7.47 -0.06 (-0.80%)

As of 08/28/2026 04:00 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Immunic NASDAQ:IMUX

$15.40 -0.90 (-5.52%)

As of 08/28/2026 04:00 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Minerva Neurosciences NASDAQ:NERV

$4.84 -0.29 (-5.65%)

As of 08/28/2026 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Talphera NASDAQ:TLPH

$1.20 -0.03 (-2.44%)

As of 08/28/2026 04:00 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLPH, NERV, IMUX, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLPH, NERV, IMUX, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLPH, NERV, IMUX, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Immunic NASDAQ:IMUX

Minerva Neurosciences NASDAQ:NERV

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLPH, NERV, IMUX, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLPH, NERV, IMUX, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLPH, NERV, IMUX, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, NERV, IMUX, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Immunic NASDAQ:IMUX

Minerva Neurosciences NASDAQ:NERV

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools